Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 2
1987 1
1988 1
1992 1
1993 1
1994 1
1997 1
2001 1
2002 2
2003 3
2004 3
2005 9
2006 9
2007 9
2008 6
2009 7
2010 11
2011 9
2012 6
2013 8
2014 11
2015 11
2016 9
2017 11
2018 7
2019 11
2020 8
2021 20
2022 14
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Results by year

Filters applied: . Clear all
Page 1
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD-1-Antikörper beim metastasierten Melanom - ein Update.
Kähler KC, Hassel JC, Heinzerling L, Loquai C, Thoms KM, Ugurel S, Zimmer L, Gutzmer R; für das Komitee „Kutane Nebenwirkungen“ der Arbeitsgemeinschaft Dermatologische Onkologie (ADO). Kähler KC, et al. J Dtsch Dermatol Ges. 2020 Jun;18(6):582-609. doi: 10.1111/ddg.14128_g. J Dtsch Dermatol Ges. 2020. PMID: 32519497 German.
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C, Mohr P, Bluhm L, Meier F, Garzarolli M, Weichenthal M, Kähler K, Grimmelmann I, Gutzmer R, Utikal J, Terheyden P, Herbst R, Haferkamp S, Pfoehler C, Forschner A, Leiter U, Ziller F, Meiss F, Ulrich J, Kreuter A, Gebhardt C, Welzel J, Schilling B, Kaatz M, Scharfetter-Kochanek K, Dippel E, Nashan D, Sachse M, Weishaupt C, Löffler H, Gambichler T, Loquai C, Heinzerling L, Grabbe S, Debus D, Schley G, Hassel JC, Weyandt G, Trommer M, Lodde G, Placke JM, Zimmer L, Livingstone E, Becker JC, Horn S, Schadendorf D, Ugurel S. Franklin C, et al. Among authors: kahler k. J Immunother Cancer. 2023 Apr;11(4):e005828. doi: 10.1136/jitc-2022-005828. J Immunother Cancer. 2023. PMID: 37028819 Free PMC article.
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.
Haist M, Stege H, Rogall F, Tan Y, von Wasielewski I, Klespe KC, Meier F, Mohr P, Kähler KC, Weichenthal M, Hauschild A, Schadendorf D, Ugurel S, Lodde G, Zimmer L, Gutzmer R, Debus D, Schilling B, Kreuter A, Ulrich J, Meiss F, Herbst R, Forschner A, Leiter U, Pfoehler C, Kaatz M, Ziller F, Hassel JC, Tronnier M, Sachse M, Dippel E, Terheyden P, Berking C, Heppt MV, Kiecker F, Haferkamp S, Gebhardt C, Simon JC, Grabbe S, Loquai C. Haist M, et al. Among authors: kahler kc. J Immunother Cancer. 2023 Sep;11(9):e007630. doi: 10.1136/jitc-2023-007630. J Immunother Cancer. 2023. PMID: 37730278 Free PMC article.
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
Bhave P, Ahmed T, Lo SN, Shoushtari A, Zaremba A, Versluis JM, Mangana J, Weichenthal M, Si L, Lesimple T, Robert C, Trojanello C, Wicky A, Heywood R, Tran L, Batty K, Dimitriou F, Stansfeld A, Allayous C, Schwarze JK, Mooradian MJ, Klein O, Mehmi I, Roberts-Thomson R, Maurichi A, Yeoh HL, Khattak A, Zimmer L, Blank CU, Ramelyte E, Kähler KC, Roy S, Ascierto PA, Michielin O, Lorigan PC, Johnson DB, Plummer R, Lebbe C, Neyns B, Sullivan R, Hamid O, Santinami M, McArthur GA, Haydon AM, Long GV, Menzies AM, Carlino MS. Bhave P, et al. Among authors: kahler kc. J Immunother Cancer. 2022 Jul;10(7):e004668. doi: 10.1136/jitc-2022-004668. J Immunother Cancer. 2022. PMID: 35793872 Free PMC article.
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon MV, Subklewe M, Tomsitz D, Ascierto PA, Dummer R, Gogas H, Lebbé C, Long GV, McArthur G, Neilan TG, Ribas A, Robert C, Schadendorf D, Zimmer L, Eigentler T, Grabbe S, Forschner A, Kähler KC, Milani V, Pföhler C, Hassel J, Gutzmer R, Loquai C, Routy B, Furness AJS, Blank C, Wolchok JD, French LE, Hauschild A, Heinzerling L. Ertl C, et al. Among authors: kahler kc. Eur J Cancer. 2024 Mar;199:113505. doi: 10.1016/j.ejca.2023.113505. Epub 2023 Dec 23. Eur J Cancer. 2024. PMID: 38262306
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoune N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM. Goldinger SM, et al. Among authors: kahler kc. Eur J Cancer. 2022 Feb;162:22-33. doi: 10.1016/j.ejca.2021.11.022. Epub 2021 Dec 21. Eur J Cancer. 2022. PMID: 34952480
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.
Bhave P, Hong A, Lo SN, Johnson R, Mangana J, Johnson DB, Dulgar O, Eroglu Z, Yeoh HL, Haydon A, Lodde GC, Livingstone E, Khattak A, Kähler K, Hausschild A, McArthur GA, Menzies AM, Long G, Wang W, Carlino MS. Bhave P, et al. Among authors: kahler k. J Immunother Cancer. 2023 Mar;11(3):e006629. doi: 10.1136/jitc-2022-006629. J Immunother Cancer. 2023. PMID: 36889810 Free PMC article.
186 results